278 related articles for article (PubMed ID: 36207751)
1. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
2. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
[TBL] [Abstract][Full Text] [Related]
3.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
4. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
5. RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Geng R; Zheng Y; Zhao L; Huang X; Qiang R; Zhang R; Guo X; Li R
Front Genet; 2020; 11():595733. PubMed ID: 33324448
[TBL] [Abstract][Full Text] [Related]
6. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
7. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
Yang J; Li H; Hu S; Zhou Y
Aging (Albany NY); 2020 Apr; 12(8):6518-6535. PubMed ID: 32339157
[TBL] [Abstract][Full Text] [Related]
8. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
9. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
10. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
Xue S; Su XM; Ke LN; Huang YG
Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
[TBL] [Abstract][Full Text] [Related]
11. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
12. Human
Rathbun LA; Magliocco AM; Bamezai AK
Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
[TBL] [Abstract][Full Text] [Related]
13. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
15. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
16. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
[TBL] [Abstract][Full Text] [Related]
17. LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior.
Fu B; Zhou M; Geng X; Jiang Y; Zeng H; Zhou X; Yu Z; Pan J; Zhu Y; Zheng H; Huang S; Gong Y; Huang D; Zhong Y
Aging (Albany NY); 2024 Jan; 16(1):714-745. PubMed ID: 38217544
[TBL] [Abstract][Full Text] [Related]
18. ACE2 maybe serve as a prognostic biomarker in breast invasive carcinoma.
Ling J; Peng N; Luo L
J Clin Lab Anal; 2022 Jun; 36(6):e24362. PubMed ID: 35373393
[TBL] [Abstract][Full Text] [Related]
19. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
